Venetoclax plus hypomethylating agents versus intensive chemotherapy for hematological relapse of myeloid malignancies after allo-HSCT.
Chen Z, Zhen S, Zhang T, Shen Y, Pang A, Yang D, Zhang R, Ma Q, He Y, Wei J, Zhai W, Chen X, Jiang E, Han M, Feng S.
Chen Z, et al. Among authors: zhang r, zhang t.
Front Oncol. 2023 Mar 23;13:1137175. doi: 10.3389/fonc.2023.1137175. eCollection 2023.
Front Oncol. 2023.
PMID: 37035180
Free PMC article.